InicioMYCOF • OTCMKTS
add
Mydecine Innovations Group Inc
Cierre anterior
0,0027 $
Intervalo anual
0,00070 $ - 0,019 $
Cap. bursátil
308,78 mil CAD
Volumen medio
16,44 mil
Relación precio-beneficio
-
Rentabilidad por dividendo
-
Bolsa de valores principal
CNSX
En las noticias
Datos financieros
Estado de resultados
Ingresos
Ingresos netos
| (CAD) | sept 2024info | Cambio interanual |
|---|---|---|
Ingresos | — | — |
Gastos operativos | 1,63 M | 85,17 % |
Ingresos netos | -1,99 M | -68,31 % |
Margen de beneficio neto | — | — |
Beneficios por acción | — | — |
EBITDA | -1,63 M | -85,14 % |
Tipo impositivo efectivo | — | — |
Balance general
Activos totales
Responsabilidades totales
| (CAD) | sept 2024info | Cambio interanual |
|---|---|---|
Efectivo y a corto plazo | 60,17 mil | 247,04 % |
Activos totales | 178,31 mil | -96,00 % |
Responsabilidades totales | 17,62 M | 60,62 % |
Patrimonio total | -17,45 M | — |
Acciones en circulación | 61,76 M | — |
Precio-valor contable | -0,01 | — |
Rentabilidad económica | -2.426,97 % | — |
Retorno sobre capital | 40,42 % | — |
Flujo de caja
Variación neta del flujo de caja
| (CAD) | sept 2024info | Cambio interanual |
|---|---|---|
Ingresos netos | -1,99 M | -68,31 % |
Efectivo de operaciones | 46,57 mil | 293,10 % |
Efectivo de inversión | — | — |
Efectivo de financiación | — | — |
Variación neta del flujo de caja | 46,57 mil | 301,45 % |
Flujo de caja libre | 388,85 mil | 111,06 % |
Información sobre la empresa
Mydecine Innovations Group, or simply Mydecine, is an American and Canadian pharmaceutical company that is developing psychedelics and entactogens as medicines.
In August 2022, it was reported that Mydecine was experiencing financial difficulties and might cease operations. However, the company was able to obtain more funding and did not shutdown. Mydecine made the first legal import of magic mushrooms into Canada in 2021.
Mydecine's drug candidates include the psychedelics psilocybin, MYCO-004, and MYCO-005 and the novel MDMA-like entactogens MYCO-002, MYCO-006, and MYCO-007.
Although the chemical structures of most of its drug candidates have not been disclosed, Mydecine has patented 5-BZT-MDMA and 6-BZT-MDMA as short-acting MDMA analogues. Wikipedia
Fundación
2020
Sitio web
Empleados
3
